John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 11,267 shares at $190.42 ($2.2M) on 2021-02-16, disclosed to the SEC on 2021-02-18.
Open-market sale of $2.2M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $189.51 | 400 | $76K | 3.5% |
| 2 | $190.42 | 1,400 | $267K | 12.3% |
| 3 | $191.63 | 2,683 | $514K | 23.7% |
| 4 | $191.63 | 2,683 | $514K | 23.7% |
| 5 | $192.61 | 451 | $87K | 4.0% |
| 6 | $192.61 | 451 |
| $87K |
| 4.0% |
| 7 | $194.60 | 600 | $117K | 5.4% |
| 8 | $195.43 | 800 | $156K | 7.2% |
| 9 | $197.36 | 633 | $125K | 5.7% |
| 10 | $197.36 | 633 | $125K | 5.7% |
| 11 | $198.08 | 233 | $46K | 2.1% |
| 12 | $199.78 | 300 | $60K | 2.8% |
| Total | $192.91 avg | 11,267 | $2.2M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |